Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQTNASDAQ:AVXLNASDAQ:BLTENYSE:CYH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$13.60-1.6%$14.73$6.99▼$17.75$1.65B1.872.36 million shs2.08 million shsAVXLAnavex Life Sciences$8.17+0.6%$8.91$3.51▼$14.44$697.49M0.821.22 million shs894,021 shsBLTEBelite Bio$61.60+1.2%$61.90$40.09▼$86.53$1.96B-1.4849,878 shs10,894 shsCYHCommunity Health Systems$3.87+1.8%$2.75$2.24▼$6.29$542.98M1.992.26 million shs4.00 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics-1.59%-0.33%+5.10%+10.48%+67.28%AVXLAnavex Life Sciences+0.62%-3.37%-7.37%-3.54%+89.56%BLTEBelite Bio+1.17%+1.57%+5.10%+8.89%+46.67%CYHCommunity Health Systems+1.84%+18.17%+49.42%+15.01%+3.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics2.7793 of 5 stars4.41.00.00.03.40.80.6AVXLAnavex Life Sciences3.822 of 5 stars3.71.00.04.72.70.80.6BLTEBelite Bio2.156 of 5 stars3.53.00.00.02.00.80.6CYHCommunity Health Systems3.1082 of 5 stars2.01.00.04.52.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8038.24% UpsideAVXLAnavex Life Sciences 3.33Buy$44.00438.56% UpsideBLTEBelite Bio 3.00Buy$96.6756.93% UpsideCYHCommunity Health Systems 2.00Hold$3.921.21% UpsideCurrent Analyst Ratings BreakdownLatest CYH, BLTE, AVXL, and ARQT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2025CYHCommunity Health SystemsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$3.504/11/2025CYHCommunity Health SystemsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$4.00 ➝ $3.004/9/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/9/2025CYHCommunity Health SystemsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral4/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/7/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/3/2025ARQTArcutis BiotherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/3/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/3/2025ARQTArcutis BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.003/31/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/26/2025BLTEBelite BioBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$212.82M7.62N/AN/A$0.94 per share14.47AVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/ABLTEBelite BioN/AN/AN/AN/A$3.28 per shareN/ACYHCommunity Health Systems$12.65B0.04$2.76 per share1.40($12.06) per share-0.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$262.14M-$1.04N/AN/AN/A-140.97%-119.11%-45.95%N/AAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-37.50%-34.08%N/ABLTEBelite Bio-$31.63M-$1.18N/AN/AN/AN/A-31.94%-30.73%N/ACYHCommunity Health Systems-$133M-$3.68N/A15.48N/A-4.08%N/A-0.96%7/23/2025 (Estimated)Latest CYH, BLTE, AVXL, and ARQT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million4/23/2025Q1 2025CYHCommunity Health Systems-$0.10-$0.03+$0.07-$0.10$3.10 billion$3.16 billion3/17/2025Q4 2024BLTEBelite Bio-$0.30-$0.32-$0.02-$0.32N/AN/A2/25/2025Q4 2024ARQTArcutis Biotherapeutics-$0.28-$0.09+$0.19-$0.09$60.52 million$71.36 million2/18/2025Q4 2024CYHCommunity Health Systems$0.09-$0.42-$0.51-$0.53$3.14 billion$3.27 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AAVXLAnavex Life SciencesN/AN/AN/AN/AN/ABLTEBelite BioN/AN/AN/AN/AN/ACYHCommunity Health SystemsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.672.462.38AVXLAnavex Life SciencesN/A9.459.45BLTEBelite BioN/A30.7330.73CYHCommunity Health SystemsN/A1.411.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/AAVXLAnavex Life Sciences31.55%BLTEBelite Bio0.53%CYHCommunity Health Systems84.99%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%AVXLAnavex Life Sciences11.40%BLTEBelite Bio13.29%CYHCommunity Health Systems11.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.20 million105.93 millionOptionableAVXLAnavex Life Sciences4085.37 million75.71 millionOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableCYHCommunity Health Systems66,000140.31 million125.19 millionOptionableCYH, BLTE, AVXL, and ARQT HeadlinesRecent News About These CompaniesCommunity Health Systems to Participate in 2025 RBC Capital Markets Global Healthcare ConferenceMay 14 at 12:10 PM | gurufocus.comTudor Investment Corp ET AL Has $51,000 Holdings in Community Health Systems, Inc. (NYSE:CYH)May 13 at 4:06 AM | marketbeat.comDimensional Fund Advisors LP Raises Position in Community Health Systems, Inc. (NYSE:CYH)May 13 at 3:21 AM | marketbeat.comWhat is Zacks Research's Estimate for CYH Q2 Earnings?May 11, 2025 | marketbeat.comZacks Research Issues Pessimistic Estimate for CYH EarningsMay 11, 2025 | americanbankingnews.comQ4 EPS Forecast for Community Health Systems Cut by AnalystMay 10, 2025 | marketbeat.comCaption Management LLC Cuts Stock Position in Community Health Systems, Inc. (NYSE:CYH)May 10, 2025 | marketbeat.com800,000 Shares in Community Health Systems, Inc. (NYSE:CYH) Purchased by Brevan Howard Capital Management LPMay 9, 2025 | marketbeat.comCommunity Health Systems, Inc. Announces Early Tender Results of Previously Announced Tender Offer for 6.875% Senior Unsecured Notes Due 2028May 7, 2025 | finance.yahoo.comCommunity Health Systems, Inc. (NYSE:CYH) Receives Consensus Rating of "Hold" from BrokeragesMay 6, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Purchases New Stake in Community Health Systems, Inc. (NYSE:CYH)May 5, 2025 | marketbeat.comCommunity Health Systems, Inc. (NYSE:CYH) Given Consensus Rating of "Hold" by AnalystsMay 5, 2025 | americanbankingnews.comWhitebox Advisors LLC Buys 837,338 Shares of Community Health Systems, Inc. (NYSE:CYH)May 3, 2025 | marketbeat.comVoleon Capital Management LP Takes Position in Community Health Systems, Inc. (NYSE:CYH)May 3, 2025 | marketbeat.comBarclays PLC Buys 130,538 Shares of Community Health Systems, Inc. (NYSE:CYH)May 3, 2025 | marketbeat.comCommunity Health Systems rating upgraded to ’CCC+’ by S&P Global RatingsMay 2, 2025 | investing.comCommunity Health Systems, Inc. (NYSE:CYH) Shares Acquired by Apollo Management Holdings L.P.May 2, 2025 | marketbeat.comCommunity Health Systems (CYH) Faces Challenges Due to Delayed Medicaid Payments | CYH Stock NewsMay 2, 2025 | gurufocus.comStock Traders Purchase High Volume of Put Options on Community Health Systems (NYSE:CYH)May 1, 2025 | marketbeat.comCommunity Health Systems downgraded to ’SD’ following debt repurchaseMay 1, 2025 | in.investing.comCommunity Health Q1 Earnings Top on Rising Patient Volumes, Stock Up 8%April 29, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYH, BLTE, AVXL, and ARQT Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$13.60 -0.22 (-1.59%) As of 05/14/2025 04:00 PM EasternArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Anavex Life Sciences NASDAQ:AVXL$8.17 +0.05 (+0.62%) As of 05/14/2025 04:00 PM EasternAnavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Belite Bio NASDAQ:BLTE$61.60 +0.71 (+1.17%) As of 05/14/2025 04:00 PM EasternBelite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Community Health Systems NYSE:CYH$3.87 +0.07 (+1.84%) As of 05/14/2025 03:48 PM EasternCommunity Health Systems, Inc. owns, leases, and operates general acute care hospitals in the United States. It offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. The company also provides outpatient services at primary care practices, urgent care centers, free-standing emergency departments, ambulatory surgery centers, imaging and diagnostic centers, and direct-to-consumer virtual health visits. The company was incorporated in 1996 and is headquartered in Franklin, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
